Protagonist Therapeutics, Inc. (PTGX)
Chart Events
Performance Outlook
| Previous Close | 28.02 |
| Open | 28.16 |
| Bid | 29.13 x 1000 |
| Ask | 29.23 x 1100 |
| Day's Range | 28.16 - 29.62 |
| 52 Week Range | 13.54 - 32.10 |
| Volume | 214,704 |
| Avg. Volume | 342,067 |
| Market Cap | 1.282B |
| Beta (5Y Monthly) | 1.55 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.82 |
| Earnings Date | Aug 04, 2021 - Aug 09, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 37.40 |
Fair Value
Related Research
- Zacks
Protagonist Therapeutics (PTGX) Reports Q1 Loss, Tops Revenue Estimates
Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of 5.26% and 65.04%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
- PR Newswire
Protagonist Reports First Quarter 2021 Financial Results and Provides Corporate Update
Protagonist Therapeutics (Nasdaq: PTGX) ("Protagonist" or the "Company") today reported financial results for the first quarter of 2021 ended March 31, 2021 and provided a corporate update.
- PR Newswire
Protagonist Therapeutics Reports Granting of Inducement Award
Protagonist Therapeutics, Inc. (Nasdaq: PTGX) today reported that on April 30, 2021, it issued an inducement award to Ramesh Bhatt, the Company's recently hired Vice President, Discovery Biology and Translational Research, in accordance with the terms of Dr. Bhatt's employment offer letter. The award was granted under the Protagonist Therapeutics Amended and Restated Inducement Plan, which was adopted May 29, 2018, and amended February 18, 2020.
